Neuro-Oncology News

The majority of U.S. hematologists–oncologists who use Twitter reported at least one financial conflict of interest made public through the federal Open Payments program, according to study results published in JAMA Internal Medicine.

Researchers have identified the chemical process behind the anticancer properties of piperlongumine, the compound found in the spicy Indian pepper plant.

Nearly one in five U.S. cancer survivors take medications for anxiety or depression, according to study results published in the Journal of Clinical Oncology.

Pediatric oncology patients with high degrees of symptom-related suffering appeared more likely than their parents to acknowledge the benefits of early palliative care, according to survey results.

Bruce E. Johnson, MD, FASCO, professor of medicine at Harvard Medical School and institute physician at Dana-Farber Cancer Institute, will become president of ASCO during the society’s annual meeting in June.

The Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology — held in November in Scottsdale, Arizona — featured data from key studies on targeted therapies and immunotherapies.

Exercise and psychological interventions provide greater benefit to patients than pharmaceutical drugs for reducing cancer-related fatigue, according to results of a meta-analysis.

The FDA granted orphan drug designation to epidermal growth factor receptor–targeted, doxorubicin-loaded EDV nanocells for the treatment of glioblastoma multiforme, according to the drug platform’s manufacturer.

This month’s top news includes a number of key studies in hematology and oncology.

Decreased exposure to radiation therapy has lowered incidence of subsequent malignancies in childhood cancer survivors diagnosed in the 1990s compared with those diagnosed in the 1970s, according to results of a longitudinal cohort study.